TD Asset Management Inc Lowers Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

TD Asset Management Inc decreased its position in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 35.9% during the 2nd quarter, Holdings Channel reports. The fund owned 95,006 shares of the company’s stock after selling 53,200 shares during the quarter. TD Asset Management Inc’s holdings in Apogee Therapeutics were worth $3,738,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in APGE. Darwin Global Management Ltd. acquired a new stake in Apogee Therapeutics in the first quarter valued at approximately $55,300,000. Vanguard Group Inc. raised its holdings in Apogee Therapeutics by 60.7% in the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after acquiring an additional 705,795 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Apogee Therapeutics by 51.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company’s stock valued at $77,770,000 after acquiring an additional 399,646 shares in the last quarter. Farallon Capital Management LLC acquired a new stake in Apogee Therapeutics in the first quarter valued at approximately $20,267,000. Finally, Jennison Associates LLC raised its holdings in Apogee Therapeutics by 192.0% in the first quarter. Jennison Associates LLC now owns 302,892 shares of the company’s stock valued at $20,127,000 after acquiring an additional 199,148 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insiders Place Their Bets

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the sale, the chief executive officer now owns 1,434,487 shares of the company’s stock, valued at $58,268,861.94. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the sale, the chief executive officer now owns 1,434,487 shares of the company’s stock, valued at $58,268,861.94. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Carl Dambkowski sold 7,335 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $40.67, for a total transaction of $298,314.45. Following the sale, the insider now directly owns 287,458 shares in the company, valued at approximately $11,690,916.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,995 shares of company stock valued at $5,218,774. 36.10% of the stock is owned by corporate insiders.

Apogee Therapeutics Stock Up 2.2 %

Shares of NASDAQ:APGE opened at $50.62 on Thursday. The firm’s 50 day moving average price is $46.47 and its 200 day moving average price is $49.38. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -9.64 and a beta of 2.75. Apogee Therapeutics, Inc. has a fifty-two week low of $14.19 and a fifty-two week high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.60). On average, equities analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.